The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Alexion Pharmaceuticals (I); Alexion Pharmaceuticals (I); Jazz Pharmaceuticals (I); Jazz Pharmaceuticals (I); Omeros (I); Omeros (I)
Consulting or Advisory Role - Alexion Pharmaceuticals (I); Jazz Pharmaceuticals (I); Omeros (I)
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Epizyme (Inst); Epizyme (Inst); Janssen (Inst); Janssen (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Pfizer (Inst); Seagen (Inst); Seagen (Inst); Takeda (Inst); Takeda (Inst); Taris (Inst); Taris (Inst)
Expert Testimony - Bracco Diagnostics; Bracco Diagnostics
Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.
 
Daniel Simmons
Employment - AstraZeneca; AstraZeneca
 
Maral DerSarkissian
Employment - Analysis Group
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Kiniksa (Inst); LivaNova (Inst); Mallinckrodt (Inst); Medtronic (Inst); Merck (Inst); Novartis (Inst); Novo Nordisk (Inst); Novo Nordisk (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Seagen (Inst); Takeda (Inst); Vertex (Inst); ViiV Healthcare (Inst)
Expert Testimony - Bayer (Inst)
 
Rahul Shenolikar
Employment - AstraZeneca; AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca; Biogen; CVS; Johnson & Johnson
Research Funding - Johnson & Johnson (I); Johnson & Johnson (I)
 
Min-Jung Wang
Consulting or Advisory Role - AstraZeneca (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Greenwich Biosciences (Inst); Greenwich Biosciences (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Sanofi (Inst); Sanofi (Inst); Takeda (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Greenwich Biosciences (Inst); Greenwich Biosciences (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Sanofi (Inst); Sanofi (Inst); Takeda (Inst); Takeda (Inst)
 
Angela Lax
Research Funding - Alkermes (Inst); Alkermes (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Epizyme (Inst); Epizyme (Inst); Janssen (Inst); Janssen (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi (Inst); Takeda (Inst); Takeda (Inst); Teva (Inst); Teva (Inst); Vertex (Inst); Vertex (Inst)
 
Aruna Muthukumar
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Kiniksa (Inst); Kiniksa (Inst); MyoKardia (Inst); MyoKardia (Inst); Pfizer (Inst); Pfizer (Inst); Vertex (Inst); Vertex (Inst)
 
François Laliberté
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Janssen (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst)
 
Mei Sheng Duh
No Relationships to Disclose